Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Spero Therapeutics (SPRO) Income towards Parent Company (2016 - 2025)

Historic Income towards Parent Company for Spero Therapeutics (SPRO) over the last 10 years, with Q3 2025 value amounting to -$7.4 million.

  • Spero Therapeutics' Income towards Parent Company rose 5828.48% to -$7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$43.4 million, marking a year-over-year decrease of 72916.42%. This contributed to the annual value of -$68.6 million for FY2024, which is 35661.29% down from last year.
  • As of Q3 2025, Spero Therapeutics' Income towards Parent Company stood at -$7.4 million, which was up 5828.48% from -$1.7 million recorded in Q2 2025.
  • In the past 5 years, Spero Therapeutics' Income towards Parent Company registered a high of $55.1 million during Q4 2023, and its lowest value of -$30.1 million during Q1 2022.
  • Moreover, its 5-year median value for Income towards Parent Company was -$13.9 million (2025), whereas its average is -$10.1 million.
  • In the last 5 years, Spero Therapeutics' Income towards Parent Company surged by 20021.88% in 2022 and then crashed by 45402.19% in 2024.
  • Quarter analysis of 5 years shows Spero Therapeutics' Income towards Parent Company stood at -$27.4 million in 2021, then soared by 200.22% to $27.5 million in 2022, then skyrocketed by 100.51% to $55.1 million in 2023, then tumbled by 137.03% to -$20.4 million in 2024, then skyrocketed by 63.82% to -$7.4 million in 2025.
  • Its last three reported values are -$7.4 million in Q3 2025, -$1.7 million for Q2 2025, and -$13.9 million during Q1 2025.